The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine
Preclinical studies suggest that some effects of conventional chemotherapy, and in particular, gemcitabine, are mediated through enhanced antitumor immune responses. The objective of this study was to use material from a randomized clinical trial to evaluate whether patients with preexisting immune...
Guardado en:
Autores principales: | Elisabeth S Stovgaard, Karama Asleh, Nazia Riaz, Samuel Leung, Dongxia Gao, Lise B Nielsen, Anne-Vibeke Lænkholm, Eva Balslev, Maj-Britt Jensen, Dorte Nielsen, TO Nielsen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Taylor & Francis Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7ccbadbafb984c0b806440d8a1a51c48 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Prior anti-CAFs break down the CAFs barrier and improve accumulation of docetaxel micelles in tumor
por: Pang N, et al.
Publicado: (2018) -
Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck
por: Ammar Sukari, et al.
Publicado: (2015) -
Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma
por: Gong DJ, et al.
Publicado: (2013) -
Probiotics for the Treatment of Docetaxel-Related Weight Gain of Breast Cancer Patients—A Single-Center, Randomized, Double-Blind, and Placebo-Controlled Trial
por: Zhang Juan, et al.
Publicado: (2021) -
Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles
por: Chen Z, et al.
Publicado: (2018)